Table 4.
Covariates3 | df | Wald’s χ² | p value | OR | 95%-CI |
---|---|---|---|---|---|
Sex, women vs. men | 1 | 2.686 | 0.101 | 0.92 | 0.83-1.03 |
Age, every additional year | 1 | 0.705 | 0.401 | 1.00 | 0.99-1.00 |
Education, with university degree vs. without | 1 | 1.901 | 0.168 | 1.10 | 0.96-1.26 |
SES | |||||
Medium vs. low | 1 | 0.115 | 0.735 | 1.02 | 0.90-1.17 |
High vs. los | 1 | 2.727 | 0.099 | 0.84 | 0.69-1.03 |
Physical comorbidity, yes vs. no | |||||
Arterial hypertension | 1 | 0.163 | 0.687 | 0.98 | 0.88-1.09 |
Hyperlipidemia | 1 | 0.443 | 0.506 | 0.96 | 0.87-1.07 |
Thyroid disease | 1 | 2.960 | 0.085 | 1.10 | 0.99-1.24 |
Cardiac arrhythmia | 1 | 1.044 | 0.307 | 1.09 | 0.93-1.28 |
Diabetes mellitus | 1 | 0.165 | 0.684 | 1.04 | 0.88-1.23 |
Any cancer | 1 | 0.576 | 0.448 | 0.94 | 0.80-1.11 |
Coronary heart disease/angina pectoris | 1 | 0.017 | 0.897 | 1.02 | 0.75-1.40 |
Myocardial infarction | 1 | 1.723 | 0.189 | 1.28 | 0.89-1.84 |
Stroke | 1 | 0.001 | 0.972 | 1.01 | 0.70-1.44 |
Cardiac insufficiency | 1 | 0.032 | 0.857 | 0.97 | 0.68-1.38 |
Epilepsy | 1 | 1.620 | 0.203 | 0.77 | 0.51-1.15 |
Peripheral artery occlusive disease/intermittent claudication | 1 | 0.495 | 0.482 | 0.84 | 0.51-1.37 |
Parkinson’s disease | 1 | 0.312 | 0.576 | 0.76 | 0.29-1.98 |
Multiple sclerosis | 1 | 0.311 | 0.577 | 0.79 | 0.35-1.81 |
Depressive symptomatology | |||||
CES-D score, every additional point | 1 | 0.054 | 0.816 | 1.00 | 0.99-1.01 |
Anxiety | |||||
GAD-7 score, every additional point | 1 | 0.446 | 0.504 | 1.01 | 0.99-1.03 |
Cognition3 | |||||
VFT, every additional stated animal | 1 | 0.026 | 9.871 | 1.00 | 0.99.1.01 |
1missing data for n = 1,874 (21.2%) of the 8,834 participants; 2Nagelkerke’s R² of the model = 0.004; 3The cognitive test results of Trail Making Test (TMT) A, TMT B and TMT ratio score B/A could not be additionally included into this regression model (model I) because the cognitive test results were not independent from each other. As a result, three additional regressions models (II-IV) were calculated including TMT A result (model II), TMT B result (model III), and TMT ratio score B/A result (model IV) instead of VFT test result as cognitive covariate. In these models, the different TMT tests results were also not significantly associated with having memory-related SCS: Every additional second in TMT A yielded an OR = 1.00 (95%-CI = 0.99-1.00; Wald’s χ² = 0.486, df=1, p=0.486; model II), every additional second in TMT B yielded an OR = 1.00 (95%-CI = 1.00-1.00; Wald’s χ² = 0.100, df=1, p=0.752; model III), and higher TMT ratio score B/A an OR =1.00 (95%-CI = 0.95-1.05; Wald’s χ² = 0.010, df=1, p=0.922; model IV). The replacement of the VFT test score by the other cognitive test results in regression model II-IV did not change the (non-significant) association of the other covariates with having memory-related SCS
CES-D Center of Epidemiologic Studies Depression Scale, CI confidence interval, GAD-7 Generalized Anxiety Disorder Screener, df degree of freedom, OR odds ratio, SES socio-economic status, SCS subjective cognitive symptoms VFT Verbal Fluency Test